A bone marrow transplant treats leukemia in two ways: it replaces cancerous bone marrow with healthy stem cells that produce normal blood cells, and in the case of donor transplants, it introduces a new immune system that actively hunts down and kills surviving leukemia cells. That second effect, called the graft-versus-leukemia effect, is what makes transplant uniquely powerful compared to chemotherapy alone. Five-year overall survival for acute myeloid leukemia patients after transplant is roughly 56%, and about 52% remain disease-free at the five-year mark.
Why Chemotherapy Alone Isn’t Always Enough
Chemotherapy can push leukemia into remission, meaning the cancer is no longer detectable on standard tests. But for high-risk forms of the disease, tiny numbers of leukemia cells often survive and eventually cause a relapse. A bone marrow transplant addresses this problem by going further than chemotherapy can: it wipes out the bone marrow entirely and rebuilds it from scratch, ideally with a donor’s healthy cells that carry their own cancer-fighting capability.
The Conditioning Phase: Clearing the Way
Before any new stem cells are infused, you go through a conditioning regimen of high-dose chemotherapy, sometimes combined with full-body radiation. This phase accomplishes three things at once. It destroys as many remaining leukemia cells as possible. It clears physical space inside the bone marrow for the new stem cells to take root. And it suppresses your immune system enough to prevent your body from rejecting the donor cells.
This conditioning is intense. It eliminates virtually all blood-forming cells in the marrow, which means your blood counts drop to dangerously low levels. You’ll be highly vulnerable to infection and bleeding for weeks afterward, which is why this entire process takes place in a hospital with strict infection precautions.
How Donor Cells Fight Leukemia
The most important anti-leukemia benefit of transplant comes from the donor’s immune cells, particularly their T cells. Once the donor’s stem cells engraft and start producing a new immune system inside your body, those immune cells recognize leftover leukemia cells as foreign and attack them. This graft-versus-leukemia effect is a clinically well-established phenomenon that maintains remission long after the transplant itself.
Multiple types of immune cells contribute. Donor T cells are the primary drivers, directly killing leukemia cells they identify as abnormal. Natural killer cells also play a role, showing particular effectiveness against myeloid leukemia cells. Even certain antibodies produced by the new immune system have been found to target leukemia-specific markers. In patients who relapse after transplant, doctors can sometimes infuse additional donor immune cells to reignite this effect.
The catch is that the same immune activity responsible for killing leukemia can also attack your healthy tissues. The donor’s immune cells don’t perfectly distinguish between “leukemia” and “unfamiliar but normal.” This overlap is the central tension of the entire procedure.
Allogeneic vs. Autologous Transplants
There are two broad categories of bone marrow transplant, and they work differently against leukemia. An allogeneic transplant uses stem cells from a donor, either a matched sibling, an unrelated volunteer, or cord blood. This is the standard approach for high-risk acute myeloid leukemia and many other aggressive blood cancers because it provides the graft-versus-leukemia effect.
An autologous transplant uses your own stem cells, collected and frozen before high-dose chemotherapy, then returned to you afterward. This approach lets doctors give much higher doses of chemo than the body could otherwise survive, but it lacks the immune-driven cancer-fighting benefit of donor cells. Autologous transplants are more commonly used for lymphomas and certain other blood cancers rather than for leukemia specifically.
Finding a Matching Donor
For an allogeneic transplant, the donor’s tissue type needs to closely match yours. This match is based on proteins called HLA markers on the surface of your cells. Doctors typically evaluate eight key HLA markers, and an ideal unrelated donor matches on all eight. A matched sibling is evaluated on at least six markers. When a perfect match isn’t available, a donor matching on seven of eight markers can be considered, though with somewhat higher risk. Umbilical cord blood requires a less stringent match, needing at least four of six key markers, which makes it a useful option when no well-matched adult donor exists.
Siblings have roughly a 25% chance of being a full match. For patients without a matched sibling, registries of volunteer donors and cord blood banks are searched. Half-matched (haploidentical) family donors, such as a parent or child, are increasingly used as well, requiring at least a four-of-eight match with specific restrictions on how mismatches are distributed.
How Stem Cells Are Collected and Infused
About 70% of allogeneic transplants use stem cells collected from the donor’s bloodstream rather than directly from the bone marrow. In this approach, the donor receives injections for several days that coax stem cells out of the marrow and into the circulating blood, where they’re filtered out through an IV line. The traditional method involves extracting marrow directly from the pelvic bone under anesthesia, which is still used in certain situations.
The infusion itself is surprisingly simple from your perspective. The stem cells are delivered through a central IV line, much like a blood transfusion. The cells find their way to the bone marrow on their own and begin producing new blood cells.
Engraftment and Early Recovery
After infusion, you wait. It takes at least 8 to 14 days before blood counts show any sign of recovery. Neutrophils, the white blood cells critical for fighting infection, should reach a minimum safe level by 30 days after transplant. Platelet recovery takes longer, and you’ll typically need platelet transfusions for three to six weeks, sometimes more.
During this waiting period, your immune system is essentially nonexistent. Even minor infections can become life-threatening. Most patients spend several weeks in the hospital during this phase, and even after discharge, close monitoring continues for months.
Graft-Versus-Host Disease
The most significant complication of donor transplants is graft-versus-host disease, where the donor immune cells attack your healthy organs. Acute graft-versus-host disease can develop in up to 50% of patients who receive cells from an HLA-matched sibling, and rates can be higher with less well-matched donors. It typically strikes within the first 100 days and most commonly affects the skin (in about 70% of cases), the digestive tract (74%), and the liver (44%).
Chronic graft-versus-host disease develops later and can affect a wider range of organs, including the lungs, eyes, and joints. Reported rates range from 6% to 80% depending on the donor type, stem cell source, and other factors. Mild graft-versus-host disease may actually be a favorable sign, since it indicates the donor immune system is active and likely also attacking any remaining leukemia cells. Severe cases, however, can be debilitating or fatal and require long-term immunosuppressive treatment.
Long-Term Health After Transplant
Surviving the first year is a major milestone, but transplant survivors face elevated health risks for years or even decades afterward. The high-dose chemotherapy and radiation used in conditioning can damage organs and increase the risk of secondary cancers. These secondary cancers fall into three categories: blood cancers like a new leukemia or lymphoma, which tend to appear relatively early after transplant, and solid tumors such as breast, skin, or colon cancers, which have a longer latency period.
Survivors who received full-body radiation need particular monitoring. Women who received chest radiation of 20 or more units (gray) are recommended to begin annual mammograms and breast MRIs starting eight years after radiation or at age 25, whichever comes later. Colon cancer screening via colonoscopy is recommended every five years beginning 10 years after abdominal radiation or at age 35. Annual skin exams and regular oral exams are standard for all transplant survivors.
Beyond cancer screening, survivors are monitored for hormonal changes, bone density loss, heart and lung function, cataracts, and fertility issues. Chronic graft-versus-host disease itself can persist for years, affecting quality of life and requiring ongoing treatment. Despite these challenges, many transplant survivors return to work, school, and normal daily activities within a year of their procedure.